Lybalvi Offers Safer Option For Patients With Schizophrenia And Bipolar I Disorder
Lybalvi (olanzapine/samidorphan), a new antipsychotic drug approved by the U.S. Food and Drug Administration (FDA)…
Articles
FDA Approves Lytgobi For Treatment Of Intrahepatic Cholangiocarcinoma With FGFR2 Gene Abnormalities
The U.S. Food and Drug Administration (FDA) has approved a novel targeted drug, Lytgobi (Futibatinib),…
Minjuvi (Tafasitamab) Approved For Marketing In Mexico Brings New Hope To Patients with Refractory Lymphoma
March 2025 Knight Therapeutics announced that its anti-CD19 monoclonal antibody drug Minjuvi (tafasitamab) has been…
Nurtec ODT (Rimagipam): The Dual-Action Oral Dissolving Tablet That Revolutionizes Migraine Treatment
Migraines afflict more than one billion people worldwide, and their attacks of severe headache, light…
Nebido Long-Acting Injectable: An Important Breakthrough In Global Men’s Health Management
In recent years, Testosterone Replacement Therapy (TRT) has become one of the hotspots in the…
Ontozry Approved In EU For Refractory Epilepsy Treatment, Clinical Data Demonstrate Significant Efficacy
The European Medicines Agency (EMA) recently approved Ontozry (cenobamato) for the treatment of refractory focal…
Ogsiveo (Nirogacestat) Emerges As First Targeted Therapy For Desmoid Tumors Offering New Hope For Patients
April 12, 2025 — In a landmark advancement for rare cancer treatment, Ogsiveo® (nirogacestat) has solidified its position…
FDA-Approved Ojjaara (Momelotinib) Emerges As Breakthrough Treatment For Myelofibrosis With Anemia
April 12, 2025 — The U.S. Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) as the first…
Rytelo (Imestat): First Inhibitor Offers New Hope For Patients With Transfusion-Dependent MDS
On June 6, 2024, the U.S. Food and Drug Administration (FDA) granted approval for Rytelo™…
Qelbree: A Drug That Brings New Hope For Specific Needs
Recently, Qelbree has attracted a lot of attention in the pharmaceutical field.Qelbree focuses on specific…